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Abstract 
Allergic rhinitis has a very high burden regarding both direct and indirect costs. This makes essential in the manage-
ment of AR to reduce the clinical severity of the disease and thus to lessen its costs. This particularly concerns allergen 
immunotherapy (AIT), that, based on its immunological action on the causes of allergy, extends its benefit also after 
discontinuation of the treatment. From the pharmacoeconomic point of view, any treatment must be evaluated 
according to its cost-effectiveness, that is, the ratio between the cost of the intervention and its effect. A favorable 
cost-benefit ratio for AIT was defined, starting from the first studies in the 1990s on subcutaneous immunotherapy 
(SCIT) in AR patients, that highlighted a clear advantage on costs over the treatment with symptomatic drugs. Such 
outcome was confirmed also for sublingual immunotherapy (SLIT), that has also the advantage on SCIT to be free of 
the cost of the injections. Here we review the available literature on pharmacoeconomic data for SLIT with the 5-grass 
pollen tablets.
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Background
The steadily increasing prevalence of allergic disorders, 
including allergic rhinitis (AR), asthma, and atopic der-
matitis, with global figures currently corresponding to 
more than 20% of the general population [1–4] results 
in a relevant individual and social economic burden. 
For example, concerning AR, in a retrospective analy-
sis performed in the 2000s using data from a US health 
plan covering about 15 million patients, the mean total 
costs per year related to rhinitis were $657 per patient, 
the primary contributor being outpatient visits [5]. The 
economic burden includes direct costs, that are related 
to drug treatment and visits at physician office, and indi-
rect costs, that are associated to reduced/missed work 
productivity [6]. In the late 1990s the cost for AR in the 
US were estimated in $4.5 billion for direct and $3.4 
billion for indirect costs, respectively, [7] and by 2005 
total expenditures to treat AR reached $11.2 billion [8]. 
In Europe, a study conducted in 2003 found a mean 
annual cost of €1089 for child/adolescents and €1543 
per adults, respectively, with predominance of indirect 
costs in adults (about 50%) compared with children (6%), 
in whom however the estimate did not include school 
absences [9]. A probabilistic cost of illness study in Italy 
estimated a global economic burden associated with res-
piratory allergies and their main co-morbidities of €7.33 
billion (95% CI: €5.99–€8.82). A percentage of 27.5% 
was associated with indirect costs and 72.5% with direct 
costs [10]. A very recent study from UK on 1000 adults 
patients with seasonal AR demonstrated that limiting 
the assessment to absenteeism (on average, 4 days/year) 
a cost of £1.14 billion/year was estimated [11]. Pharma-
coeconomics is the scientific discipline that analyzes 
the value of different drug therapies, serving to guide 
the optimal allocation of healthcare resource by stand-
ardized and scientifically solid methods [12]. From the 
pharmacoeconomic point of view, any drug treatment 
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must be evaluated according to its cost-effectiveness, the 
cost referring to the resource expenditure for the inter-
vention, that is usually measured in pecuniary terms 
[13]. For example, in AR first generation antihistamines 
may impair mental performances (due to their sedating 
effects) more than in untreated patients [14] and thus rise 
indirect cost. By a global therapeutic approach to AR, any 
preventive strategy that is aimed at reducing the severity 
of the rhinitis is likely to lessen its costs, and this particu-
larly concerns allergen immunotherapy (AIT).
Cost effectiveness of allergen immunotherapy
Allergen immunotherapy is aimed at reducing the symp-
toms of allergy by increasing the tolerance to the admin-
istered allergen and modifying the natural history of the 
allergic disease [15]. The first pharmaco-economic stud-
ies were conducted in the 1990s in patients treated with 
subcutaneous immunotherapy (SCIT). Their results, 
that are summarized in Table 1, were favorable, showing 
significant reductions of direct and indirect costs. The 
cost saving reaches its maximum when SCIT is stopped 
after the recommended 3  years of treatment and con-
tinues to work due to the persistent modification of the 
immunological response to the specific allergen. This 
was apparent in a study on patients from Italy with AR 
and asthma induced by sensitization to Parietaria pol-
len, who underwent 3  years of SCIT by a Parietaria 
judaica extract or with symptomatic drugs [19]. The 
patient were evaluated before SCIT initiation and then 
each year for a period of 6 years during the pollen period 
of Parietaria by measuring the nose, eye, and lung symp-
tom scores, also registering by diary cards the drug 
consumption. The data obtained showed a significant 
difference in favor of SCIT plus drug treatment vs. only 
drug treatment. The cost reduction was about 15% at the 
2nd year and 48% at the 3rd year, when a high statisti-
cal significance was detected. This was then maintained 
until the 6th year, i.e. 3  years after discontinuing SCIT, 
when the reduction of cost was 80%, with a net saving 
corresponding to €623 per year for each patient at the 
final evaluation.
On the other hand, a recent study showed that the 
cost-saving may also occur early. In fact, a retrospective 
analysis based on Florida Medicaid claims estimated the 
mean 18-month health care cost of 4967 patients with 
newly diagnosed AR who were treated for the first time 
with SCIT compared with 19,278 control subjects treated 
only with drugs [24]. In SCIT-treated patients a mean 
18-month total health care cost of $6637 was calculated, 
compared with $10,644 in controls (38% lower in SCIT-
treated, P  <  0.0001). Significant savings were detected 
within 3 months from starting SCIT, with no significant 
difference between the savings observed in SCIT-treated 
adults and SCIT-treated children ($4397 vs. $3965). The 
fact that the more recently introduced sublingual immu-
notherapy (SLIT) is performed by patients at home and 
thus is free of the cost of injections suggests that the cost-
effectiveness of SLIT may be even better than SCIT.
Studies on sublingual immunotherapy
The first study, that involved one Allergy center in 
Italy, evaluated the cost effectiveness of SLIT in pedi-
atric patients with respiratory allergy [25]. A group of 
135 children with AR and asthma was studied, the data 
concerned 1-year prior to receive SLIT and 3-year after 
starting SLIT. The outcome measures were the number 
of disease exacerbations, visits, and missed nursery or 
school days, including direct and indirect costs. Forty-
six patients had perennial allergy and 89 had seasonal 
allergy. All outcome measures showed a considerable 
reduction during SLIT compared to the previous 1-year 
period. The annual cost/patient averaged to €2672 before 
starting SLIT and to €629/year during SLIT, with compa-
rable results for allergen subgroups. These findings sug-
gested that SLIT was able to reduce the global cost of AR. 
Such outcome was confirmed in a number of subsequent 
studies, that were reviewed in 2008 by Berto et  al. [26] 
In particular, a study performed in patients with AR from 
Table 1 Studies on pharmacoeconomics of subcutaneous immunotherapy
Author (year) Patients Allergen Study duration 
(years)
Results
Buchner (1995) [16] Adults Pollen, mites 10 −54% costs for symptomatic treatment
Schadlich (2000) [17] Adults Pollen, mites 10 €332-608 saving per patient
Petersen (2005) [18] Adults Pollen 4 €203 saving per patient
Ariano (2006) [19] Adults Pollen 6 48% money saving at year 4
Omnes (2007) [20] Adults & children Pollen, mites 6 €1327 saving per patient for pollen, €393 for mites
Hankin (2008) [21] Children Pollen, mites 1.5 €308 6-month saving per patient
Hankin (2010) [22] Children Pollen, mites 1.5 −34% total healthcare cost per patient
Wang (2011) [23] Adults Pollen, mites 1.5 −41% total healthcare cost per patient
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Czech Republic compared directly the treatment with the 
two forms of AIT (SCIT and SLIT) and only drug treat-
ment for 3  years. The mean direct cost per patient was 
estimated in €482 for SCIT and €416 for SLIT, a SLIT-
treated patient paying more than a SCIT-treated patient 
for allergen extracts (€72 vs. €55) but paying less for out-
of-pocket costs (€176 vs. €255). The figure of direct and 
indirect costs over the 3-year treatment was €1004 for 
SCIT and €684 for SLIT [27].
Studies on the 5‑grass pollen tablets
The 5-grass pollen tablets, that contain pollen extracts 
from Pooideae family (Anthoxanthum odoratum, Poa 
pratensis, Dactylis glomerata, Phleum pratense, and 
Lolium perenne) were approved and registered, based on 
regulatory large trials that fulfilled all requirements by the 
European Medicine Agency (EMA) in Europe and Food 
and Drug Administration (FDA) in the US [28–30]. The 
5-grass pollens tablets were accepted for full reimburse-
ment by the Agenzia Italiana del Farmaco (AIFA) [31], 
with the indication for AR and/or conjunctivitis treat-
ment in adult or pediatric patients (over 5  years) with 
severe symptoms, by a pre-co-seasonal course of admin-
istration. The first study on the cost-effectiveness of 
5-grass tablets was conducted by Ruggeri et al., based on 
post hoc analysis of the VO34.04 and VO53.06 trials [28, 
29]. The economic data from the perspective of Italian 
third-party payer, as well as a societal perspective based 
on the costs related to the losses of productivity were 
analyzed [32]. Medication effectiveness was assessed 
using as main outcome parameter the Quality Adjusted 
Life Years (QALYs), that is a multi-attribute scale gener-
ating a single numeric index of health-related Quality of 
life (Qol) of patients ranging from 0 (death) to 1 (perfect 
health). A decision tree modeling the likely outcomes and 
costs for adults and children with a low, medium, and 
high score of allergic symptoms was used. Compared to 
placebo, the 5-grass tablet treatment resulted in 0.127 
QALYs in patients with moderate allergic symptoms 
and in 0.143 QALYs in patients with severe symptoms. 
The 5-grass pollen tablet treatment had a cost of €1024/
QALY for patients with moderate symptoms and €1035/
QALY for those with severe symptoms. The authors con-
cluded that, based on the cost-effectiveness for adult 
patients with moderate to severe AR, the 5-grass tablet 
should be carefully considered when choosing the man-
agement strategy for AR [32]. An investigation conducted 
in Germany on the outcomes, costs and cost-effective-
ness compared the 5-grass tablets to the one-grass tab-
let and the one-grass extract for subcutaneous injection, 
using as control the drug treatment alone for grass pol-
len-induced AR. A Markov model was used to assess the 
costs and outcomes of a 3-year treatment for a period of 
9 years, estimating the treatment efficacy by an indirect 
comparison of published clinical trials on grass pollen 
immunotherapy with placebo. The analysis included both 
public and private health insurance payments. Outcomes 
were reported as QALYs and symptom-free days. The 
5-grass tablet had a predicted cost-utility ratio vs. drug 
treatment of €14,728 per QALY, with incremental costs 
corresponding to €1356 and incremental QALYs to 0.092. 
SLIT with the 5-grass tablet was the prevailing strategy 
compared to one-grass tablet and SCIT, with incremen-
tal costs estimated in −€1142 and −€54 and incremental 
QALYs estimated in 0.015 and 0.027, respectively. Even 
though the indirect comparison involving several steps 
to assess the treatment effects was a limitation, the study 
suggested that the 5-grass tablet was cost-effective com-
pared to one-grass tablet and injective immunotherapy 
[33]. In a recent study, the same authors compared, by 
reviewing the literature and performing meta-analysis 
and cost-effectiveness analysis the effects and costs of 
the 5-grass tablet vs. a mix of allergoids for SCIT in grass 
pollen allergic rhinoconjunctivitis. As for the previous 
study, a Markov model with a 9 year time length was used 
to assess the costs and effects of a 3-year-long treatment. 
Drug acquisition and medical costs, estimates for use 
of the resources, persistence of AIT and asthma occur-
rence were obtained from published sources. The analysis 
was performed from the payer’s perspective in Germany, 
that includes payments of NHS and additional payments 
by insurants. A cost-utility ratio of the 5-grass tablet vs. 
the mix of injectable allergoids of €12,593 per QALY was 
observed, with predicted incremental costs and QALYs 
corresponding to €458 and 0.036, respectively. The prob-
ability of the 5-grass tablet to be the most cost-effective 
treatment option was estimated in 76% at a willingness-
to-pay threshold of €20,000. These data confirmed the 
cost-effectiveness of the 5-grass tablet also over SCIT 
with a mix of allergoids [34].
Conclusions
In times when a rigid control of expenditures for NHSs 
is needed, the cost-effectiveness of medical treatments 
is of paramount importance. Among treatment options 
for AR, AIT (that includes SCIT and SLIT) has exclu-
sive features, that include the ability to alter the natural 
history of allergy and to extend its effectiveness, differ-
ently from drug treatment, to several years after discon-
tinuing the therapy. A growing bulk of data indicates that 
SCIT and SLIT may be very advantageous to the health-
care systems [35–38]. However, the pharmacoeconomic 
advantage demonstrated in optimally performed studies 
needs to be confirmed by real-life experiences. In fact, in 
the latest years data showing a poor adherence to long-
term SLIT, with a minority of patients completing the 
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recommended 3 years of treatment duration, [39] makes 
unlikely that the cost effectiveness is achieved when SLIT 
is abandoned before reaching a duration able to extend 
the benefit on symptoms and use of drugs over time. This 
issue needs to be considered by all specialists concerned 
in this treatment.
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